Alkem Laboratories is expected to report its June 2026 quarter with analysts optimistic about its steady growth outlook, prompting upward revisions in revenue and profit estimates for 2027 and beyond.
Alkem Laboratories is due to report its quarter ended June 2026 numbers on 14 August, with analysts expecting revenue of ₹37,827.14 million and earnings of ₹49.10 per share, according to GuruFocus. The same data set points to full-year 2027 revenue of ₹164,857.59 million and earnings of ₹199.98 per share, suggesting the market is still modelling steady growth despite a mixed finish to the previous year.
The forecast backdrop has improved over the past 90 days. GuruFocus says revenue estimates for 2027 have edged up from ₹163,022.03 million to ₹164,857.59 million, while earnings expectations have climbed from ₹188.93 per share to ₹199.98 per share. For 2028, both revenue and profit estimates have also moved higher, indicating analysts have become a little more constructive on the Indian drugmaker’s medium-term outlook.
Recent results show why expectations remain finely balanced. In the quarter ended 31 March 2026, Alkem beat revenue estimates with sales of ₹36,033.20 million, but earnings of ₹19.77 per share fell well short of the ₹45.15 forecast, and the stock ended the day unchanged, GuruFocus said. MarketScreener reported that full-year sales reached ₹147,122.7 million, underscoring a business that can still grow on the top line even when margins and bottom-line delivery prove less consistent.
More recently, LiveMint and Business Standard reported that in the June 2026 quarter Alkem posted revenue of about ₹3,371 crore, up 11.2% from a year earlier, while net profit rose about 22% to ₹664.3 crore. Those reports said Indian sales and overseas business both contributed to the advance, with EBITDA up 21.4% and an EBITDA margin of 21.9%. Against that backdrop, broker sentiment remains broadly positive: GuruFocus says the average 12-month target from 19 analysts is ₹5,912.26, implying 7.89% upside from ₹5,480, while its own GF Value model pegs fair value at ₹6,907.16, or 26.04% above the current price.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
